HLA association of amoxicillin-clavulanate–induced hepatitis

Hautekèete, M.; Horsmans, Yves; Waeyenberge, C Van; Demanet, Christian; Henrion, Jean; Verbist, Louis; Brenard, R.; Sempoux, Christine; Michielsen, P.; Yap, P; Rahier, Jacques; Geubel, André

doi:10.1016/s0016-5085(99)70404-x

Cited by 262 publications

(144 citation statements)

References 21 publications

Supporting

Mentioning

129

Contrasting

Order By: Relevance

“…In that study, HLA-A*0201 (odds ratio, 2.2) and DRB1*1501-DQB1*0602 (odds ratio, 3.3) were identified as risk factors. The DRB1*1501-DQB1*0602 association has also been reported in previous studies (Hautekeete et al, 1999;O'Donohue et al, 2000). A few HLA genotypes were shown to associate strongly with particular types of DILI: HLA-B*5701 with flucloxacillin-induced DILI in northern Europeans (odds ratio, 80.6) (Daly et al, 2009) and HLA-A*3303 with ticlopidine-induced cholestatic DILI in Japanese individuals (odds ratio, 36.5) (Hirata et al, 2008).…”

Section: Discussionsupporting

confidence: 77%

No Contribution of the ABCB11 p.444A Polymorphism in Japanese Patients with Drug-Induced Cholestasis

et al. 2015

View full text Add to dashboard Cite

European studies have revealed that the ABCB11 c.1331T>C (V444A) polymorphism (rs2287622) C-allele frequency is higher among patients with drug-induced cholestasis. Given the low incidence of this disease, however, this association has not been sufficiently elucidated. We aimed to investigate the significance of this polymorphism in Japanese patients. We determined ABCB11 V444A polymorphism frequencies and HLA genotypes in two independent drug-induced cholestasis cohorts. Expression and taurocholate transport activity of proteins from 444A variants were analyzed using Madin-Darby canine kidney II cells. In cohort 1 (n = 40), the V444A polymorphism C-allele frequency (66%) was lower than that in controls (n = 190, 78%), but this difference was not significant (P = 0.09). In cohort 2 (n = 119), comprising patients with cholestatic (n = 19), hepatocellular (n = 74), and mixed (n = 26) liver injuries, the C-allele frequency was lower among patients with cholestatic liver injury (68%) than among those with hepatocellular (75%) or mixed liver injury (83%), although this difference was not significant. In cohort 1, HLA-A*0201 was observed more frequently in patients (22%) than in controls [11%; P = 0.003; odds ratio, 2.4 (95% confidence interval, 1.4-4.0)]. Taurocholate transport activity of 444A-encoded protein was significantly lower than that of 444V-encoded protein (81% of 444V, P < 0.05) because of the reduced protein stability. In conclusion, ABCB11 444A had slightly reduced transport activity, but it did not contribute to the occurrence of drug-induced cholestasis in Japanese patients. Therefore, genetic susceptibility to acquired cholestasis may differ considerably by ethnicity.

show abstract

Section: Discussionsupporting

confidence: 77%

No Contribution of the ABCB11 p.444A Polymorphism in Japanese Patients with Drug-Induced Cholestasis

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Sharma et al 67 observed increased risk of TB hepatotoxicity with HLA-DQB1*0201 with an odds ratio of 1.9. Similarly, results identifying association between HLA gene polymorphism and predisposition to DILI particularly amoxicillin-clavulanic acid hepatotoxicity have been reported in some 84 but not others. 85 HLA class I and II gene polymorphism may have a role in the pathogenesis and biochemical expression of DILI, 85,86 and in some may have a protective role in DILI.…”

Section: Genetic Factorsmentioning

confidence: 85%

An Update on Drug-induced Liver Injury

Devarbhavi

2012

Journal of Clinical and Experimental Hepatology

143

101

View full text Add to dashboard Cite

“…The issue of genetics and family history remains unresolved with a family history of adverse reactions to beta-lactams likely more relevant in non-immediate rather than in immediate hypersensitivity reactions [67][68][69][70]. The emerging studies indicating a role for genetic predisposition [71,72] have been relatively small, largely investigating subsets of candidate genes, and have not been confirmed.…”

Section: Genetic Predispositionmentioning

confidence: 99%

Management of allergy to penicillins and other beta‐lactams

Mirakian

Leech

Krishna

et al. 2015

Clin Experimental Allergy

228

229

View full text Add to dashboard Cite

SummaryThe Standards of Care Committee of the British Society for Allergy and Clinical Immunology (BSACI) and an expert panel have prepared this guidance for the management of immediate and non-immediate allergic reactions to penicillins and other beta-lactams. The guideline is intended for UK specialists in both adult and paediatric allergy and for other clinicians practising allergy in secondary and tertiary care. The recommendations are evidence based, but where evidence is lacking, the panel reached consensus. During the development of the guideline, all BSACI members were consulted using a Web-based process and all comments carefully considered. Included in the guideline are epidemiology of allergic reactions to beta-lactams, molecular structure, formulations available in the UK and a description of known beta-lactam antigenic determinants. Sections on the value and limitations of clinical history, skin testing and laboratory investigations for both penicillins and cephalosporins are included. Cross-reactivity between penicillins and cephalosporins is discussed in detail. Recommendations on oral provocation and desensitization procedures have been made. Guidance for beta-lactam allergy in children is given in a separate section. An algorithm to help the clinician in the diagnosis of patients with a history of penicillin allergy has also been included.Keywords allergy, anaphylaxis, beta-lactam, BSACI, carbapenem, cephalosporin, children, cross-reactivity, desensitization, drug provocation test, epidemiology, hypersensitivity, monobactam, oral challenges, paediatrics, penicillin, serum-specific IgE, skin tests, Standards of Care Committee • This guideline addresses immediate and non-immediate allergic reactions to beta-lactams.• Up to 20% of drug-related anaphylaxis deaths in • Individuals with a positive skin test to an aminopenicillin but negative skin tests to penicillin determinants are likely to be sensitized to the aminopenicillin side chain. (B) In this situation, a cautious challenge to benzyl or phenoxymethyl penicillin can be considered to ascertain whether the patient has a selective penicillin allergy. (D) • If a cephalosporin is required in a patient with a clinical history of penicillin allergy and positive skin tests -the patient should undergo skin testing using a cephalosporin with a different side chain and, if negative, provocation testing should be undertaken to exclude allergy to the specific cephalosporin. (D)• If penicillin is required in a patient with a clinical history of cephalosporin allergy, skin testing should be undertaken with penicillins and, if negative, provocation testing to exclude allergy to penicillin. (B) If skin tests are positive, then penicillin avoidance or desensitization can be considered. (B)• If a cephalosporin is required by a patient with a previous reaction, skin testing to penicillins and the required cephalosporin should be carried out to establish whether sensitization is to the beta-lactam core or side chain. (B) This should be followed by either provo...

show abstract

HLA association of amoxicillin-clavulanate–induced hepatitis

Cited by 262 publications

References 21 publications

No Contribution of the ABCB11 p.444A Polymorphism in Japanese Patients with Drug-Induced Cholestasis

No Contribution of the ABCB11 p.444A Polymorphism in Japanese Patients with Drug-Induced Cholestasis

An Update on Drug-induced Liver Injury

Management of allergy to penicillins and other beta‐lactams

Contact Info

Product

Resources

About